GlaxoSmithKline PLC Director/PDMR Shareholding (2840U)
January 16 2017 - 11:01AM
UK Regulatory
TIDMGSK
RNS Number : 2840U
GlaxoSmithKline PLC
16 January 2017
GlaxoSmithKline plc (the 'Company')
Transaction notification
1. Details of PDMR/person closely associated with them
('PCA')
=== ===========================================================================
a) Name Ms E Walmsley
=== ======================== =================================================
b) Position/status CEO Designate
=== ======================== =================================================
c) Initial notification/ Initial notification
amendment
=== ======================== =================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ===========================================================================
a) Name GlaxoSmithKline plc
=== ======================== =================================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== =================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ===========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== =================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 12 January 2017
on Ordinary Shares held in the Company's
Deferred Investment Award Programme.
=== ======================== =================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ------------ ----------
GBP15.7075 489.079
------------ ----------
=== ======================== =================================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== =================================================
e) Date of the transaction 2017-01-12
=== ======================== =================================================
f) Place of the n/a
transaction
=== ======================== =================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ===========================================================================
a) Name Mr R G Connor
=== ======================== =================================================
b) Position/status President, Global Manufacturing & Supply
=== ======================== =================================================
c) Initial notification/ Initial notification
amendment
=== ======================== =================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ===========================================================================
a) Name GlaxoSmithKline plc
=== ======================== =================================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== =================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ===========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== =================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 12 January 2017,
on Ordinary Shares held in the Company's
Deferred Investment Award Programme.
=== ======================== =================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ------------ ----------
GBP15.7075 195.631
------------ ----------
=== ======================== =================================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== =================================================
e) Date of the transaction 2017-01-12
=== ======================== =================================================
f) Place of the n/a
transaction
=== ======================== =================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ===========================================================================
a) Name Mr S A Hussain
=== ======================== =================================================
b) Position/status President, Global Pharmaceuticals
=== ======================== =================================================
c) Initial notification/ Initial notification
amendment
=== ======================== =================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ===========================================================================
a) Name GlaxoSmithKline plc
=== ======================== =================================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== =================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ===========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== =================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 12 January 2017
on Ordinary Shares held in the Company's
Deferred Investment Award Programme.
=== ======================== =================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ------------ ----------
GBP15.7075 244.539
------------ ----------
=== ======================== =================================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== =================================================
e) Date of the transaction 2017-01-12
=== ======================== =================================================
f) Place of the n/a
transaction
=== ======================== =================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ==========================================================================
a) Name Mr B McNamara
=== ======================== ================================================
b) Position/status CEO, GSK Consumer Healthcare
=== ======================== ================================================
c) Initial notification/ Initial notification
amendment
=== ======================== ================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ==========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ================================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ==========================================================================
a) Description of GlaxoSmithKline plc American Depositary
the financial Shares ('ADSs')
instrument ISIN: US37733W1053
=== ======================== ================================================
b) Nature of the Increase in notional interest in ADSs following
transaction the re-investment of dividends paid to
shareholders on 12 January 2017 on ADSs
held in the Company's Deferred Investment
Award Programme.
=== ======================== ================================================
c) Price(s) and Price(s) Volume(s)
volume(s) --------- ----------
$38.9750 307.510
--------- ----------
=== ======================== ================================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== ================================================
e) Date of the transaction 2017-01-12
=== ======================== ================================================
f) Place of the n/a
transaction
=== ======================== ================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ===========================================================================
a) Name Mr D S Redfern
=== ======================== =================================================
b) Position/status Chief Strategy Officer
=== ======================== =================================================
c) Initial notification/ Initial notification
amendment
=== ======================== =================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ===========================================================================
a) Name GlaxoSmithKline plc
=== ======================== =================================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== =================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ===========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== =================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 12 January 2017
on Ordinary Shares held in the Company's
Deferred Investment Award Programme.
=== ======================== =================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ------------ ----------
GBP15.7075 195.631
------------ ----------
=== ======================== =================================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== =================================================
e) Date of the transaction 2017-01-12
=== ======================== =================================================
f) Place of the n/a
transaction
=== ======================== =================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ===========================================================================
a) Name Ms C Thomas
=== ======================== =================================================
b) Position/status Senior Vice President, Human Resources
=== ======================== =================================================
c) Initial notification/ Initial notification
amendment
=== ======================== =================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ===========================================================================
a) Name GlaxoSmithKline plc
=== ======================== =================================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== =================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ===========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== =================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 12 January 2017
on Ordinary Shares held in the Company's
Deferred Investment Award Programme.
=== ======================== =================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ------------ ----------
GBP15.7075 195.631
------------ ----------
=== ======================== =================================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== =================================================
e) Date of the transaction 2017-01-12
=== ======================== =================================================
f) Place of the n/a
transaction
=== ======================== =================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ===========================================================================
a) Name Dr P J T Vallance
=== ======================== =================================================
b) Position/status President, R&D
=== ======================== =================================================
c) Initial notification/ Initial notification
amendment
=== ======================== =================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ===========================================================================
a) Name GlaxoSmithKline plc
=== ======================== =================================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== =================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ===========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== =================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 12 January 2017
on Ordinary Shares held in the Company's
Deferred Investment Award Programme.
=== ======================== =================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ------------ ----------
GBP15.7075 244.539
------------ ----------
=== ======================== =================================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== =================================================
e) Date of the transaction 2017-01-12
=== ======================== =================================================
f) Place of the n/a
transaction
=== ======================== =================================================
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHQQLFFDFFBBBB
(END) Dow Jones Newswires
January 16, 2017 11:01 ET (16:01 GMT)
Gsk (LSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gsk (LSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024
